Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria  by Travis, William D. et al.
BAC SYMPOSIUM
Bronchioloalveolar Carcinoma and Lung Adenocarcinoma:
The Clinical Importance and Research Relevance of the
2004 World Health Organization Pathologic Criteria
William D. Travis, MD, Kavita Garg, MD, Wilbur A. Franklin, MD, Ignacio I. Wistuba, MD,
Bradley Sabloff, MD, Masayuki Noguchi, MD, Ryutaro Kakinuma, MD, Maureen Zakowski, MD,
Michelle Ginsberg, MD, Robert Padera, MD, Francine Jacobson, MD, Bruce E. Johnson, MD,
Fred Hirsch, MD, Elizabeth Brambilla, MD, Douglas B. Flieder, MD, Kim R. Geisinger, MD,
Frederik Thunnissen, MD, Keith Kerr, MD, David Yankelevitz, MD, Teri J. Franks, MD,
Jeffrey R. Galvin, MD, Douglas W. Henderson, MD, Andrew G. Nicholson, MD, Philip S. Hasleton, MD,
Victor Roggli, MD, Ming-Sound Tsao, MD, Federico Cappuzzo, MD, and Madeline Vazquez, MD*
Introduction: Advances in the pathology and computed tomogra-
phy (CT) of lung adenocarcinoma and bronchioloalveolar carcinoma
(BAC) have demonstrated important new prognostic features that
have led to changes in classification and diagnostic criteria.
Methods: The literature and a set of cases were reviewed by a
pathology/CT review panel of pathologists and radiologists who met
during a November 2004 International Association for the Study of
Lung Cancer/American Society of Clinical Oncology consensus
workshop in New York. The group addressed the question of
whether sufficient data exist to modify the 2004 World Health
Organization (WHO) classification of adenocarcinoma and BAC to
define a “minimally invasive” adenocarcinoma with BAC. The
problems of diffuse and/or multicentric BAC and adenocarcinoma
were evaluated.
Results: The clinical concept of BAC needs to be reevaluated with
careful attention to the new 2004 WHO criteria because of the major
clinical implications. Existing data indicate that patients with soli-
tary, small, peripheral BAC have a 100% 5-year survival rate. The
favorable prognostic impact of the restrictive criteria for BAC is
already being detected in major epidemiologic data sets such as the
Surveillance Epidemiology and End-Results registry. Most lung
adenocarcinomas, including those with a BAC component, are
invasive and consist of a mixture of histologic patterns. Therefore,
they are best classified as adenocarcinoma, mixed subtype. This
applies not only to adenocarcinomas with a solitary nodule presen-
tation but also to tumors with a diffuse/multinodular pattern. The
percentage of BAC versus invasive components in lung adenocar-
cinomas seems to be prognostically important. However, at the
present time, a consensus definition of “minimally invasive” BAC
with a favorable prognosis was not recommended by the panel, so
the 1999/2004 WHO criteria for BAC remain unchanged. In small
biopsy specimens or cytology specimens, recognition of a BAC
component is possible. However, it is not possible to exclude an
invasive component. The diagnosis of BAC requires thorough his-
tologic sampling of the tumor.
Conclusion: Advances in understanding of the pathology and CT
features of BAC and adenocarcinoma have led to important changes
in diagnostic criteria and classification of BAC and adenocarcinoma.
These criteria need to be uniformly applied by pathologists, radiol-
ogists, clinicians, and researchers. The 2004 WHO classification of
adenocarcinoma is readily applicable to research studies, but atten-
tion needs to be placed on the relative proportion of the adenocar-
cinoma subtypes. Other recently recognized prognostic features such
as size of scar, size of invasive component, or pattern of invasion
also seem to be important. More work is needed to determine the
most important prognostic pathologic features in lung adenocarci-
noma.
Key Words: Lung cancer, Adenocarcinoma, Bronchioloalveolar
carcinoma, Pathology, Radiology, Classification.
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On November 4 through 6, 2004, a workshop on bron-chioloalveolar carcinoma (BAC) was sponsored by the
International Association for the Study of Lung Cancer and
the American Society of Clinical Oncology in New York,
New York.1 This was a timely conference because there have
been significant advances in our understanding of the pathol-
ogy, clinical investigation, radiology, molecular biology, and
therapy of these tumors.2–4 Because of the advances in
pathologic criteria for lung adenocarcinoma/BAC and the
strong correlations with computed tomography (CT) find-
ings,5–9 a panel of pathology and radiology lung cancer
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experts was convened. Their recommendations are summa-
rized in this article.
Understanding lung adenocarcinoma and BAC is a
challenge for several reasons. First, adenocarcinoma consists
of a heterogeneous spectrum of histologic subtypes as well as
a wide variety of clinical and radiologic presentations. There
has also been considerable change in the pathologic criteria
for lung adenocarcinoma and BAC in the recent 1999 and
2004 World Health Organization (WHO) classifications. Fur-
thermore, with molecular advances and targeted therapies,
particularly against the epidermal growth factor receptor, we
are just beginning to investigate the relationship between
genetic changes and the histologic components of lung ade-
nocarcinoma.3,4,10–12
There is a need for a major cultural shift in the use of
terminology and criteria for the diagnosis of BAC/adenocar-
cinoma in the lung cancer oncology field. The New York
BAC conference was timely because it highlighted the major
disconnect between the clinical use of the term BAC and the
pathologic definition of BAC. At this meeting, it became
clear that the vast majority of adenocarcinomas with a BAC
component in North America and Europe are actually inva-
sive adenocarcinomas rather than pure BACs. Solitary, pe-
ripheral BACs as defined by the 2004 WHO classification are
much more common in Japan than in most other parts of the
world.7,9,13–17 The lung cancer oncology community has been
slow to adapt to the changes in terminology and criteria that
have occurred in the pathology and radiology fields18; hope-
fully, this will change as the clinical relevance of these
advances is appreciated.
THE 2004 WHO CLASSIFICATION OF LUNG
ADENOCARCINOMA
The histologic subclassification of lung adenocarci-
noma has evolved considerably since the original WHO
classification in 1967 (Table 1). The most significant change
was recommended in the 1999 WHO classification of lung
tumors,19 and only slight modification occurred in the 2004
WHO classification.20 In the 1999 WHO classification, the
category of adenocarcinoma with mixed subtypes was added
to the four subtypes from the 1981 WHO classification,
which consisted of acinar, papillary, BAC, and solid carci-
noma with mucus formation.21 The 1999 and 2004 WHO
classifications recognized that the mixed subtype is the most
common histologic type of lung adenocarcinoma because
most lung adenocarcinomas are histologically heterogeneous
and consist of more than one subtype.20
BAC underwent a major change in the 1999 WHO
classification. The most important change was the require-
ment that all BACs demonstrate pure lepidic growth without
invasion of stroma, blood vessels, or pleura.19,20 No criteria
were proposed for the extent of BAC in the 1981 WHO
classification, leading to lack of uniformity in the use of this
term that continues today. Now, with the narrower criteria for
BAC, the term adenocarcinoma, mixed subtype is used for
tumors that have a BAC (Figure 1A) and an invasive com-
ponent (Figure 1B). In such cases, the invasive patterns
present (acinar, papillary, or solid) should be mentioned. In
the 2004 WHO classification, the category of adenocarci-
noma, mixed subtype was moved to the top of the list of
subtypes because most adenocarcinomas consist of mixtures
rather than a single pattern.20 Three types of BAC were also
recognized, including nonmucinous (Figure 2), mucinous
(Figure 3), and mixed mucinous and nonmucinous. Nonmu-
cinous BAC is composed of varying mixtures of type II
pneumocytes and Clara cells. There is no clinical significance
to distinguishing these cell types in routine diagnosis of
nonmucinous BAC.19,20 A group of uncommon variants was
also added in the 1999 WHO classification.
TABLE 1. History of Lung Adenocarcinoma Subclassification According to the World Health Organization
196743 198121 199919 200420,21
1. Bronchogenic a. Acinar adenocarcinoma Acinar Adenocarcinoma, mixed subtype
a. Acinar b. Papillary adenocarcinoma Papillary Acinar adenocarcinoma
b. Papillary c. Bronchioloalveolar carcinoma Bronchioloalveolar carcinoma Papillary adenocarcinoma






Mixed mucinous and nonmucinous Mucinous
Solid adenocarcinoma with mucin Mixed nonmucinous and mucinous or
indeterminate
Adenocarcinoma with mixed subtypes Solid adenocarcinoma with mucin
production
Variants
Well-differentiated fetal adenocarcinoma Fetal adenocarcinoma
Mucinous (“colloid”) adenocarcinoma Mucinous (“colloid”) adenocarcinoma
Mucinous cystadenocarcinoma Mucinous cystadenocarcinoma
Signet-ring adenocarcinoma Signet-ring adenocarcinoma
Clear-cell adenocarcinoma Clear-cell adenocarcinoma
Data are from Travis WD, Garg K, Franklin WA, et al. Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar
carcinoma. J Clin Oncol 2005;23:3279–3287.
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Atypical adenomatous hyperplasia was also added begin-
ning in the 1999 WHO classification as a preinvasive lesion for
lung adenocarcinoma.19,20 It consists of a localized, millimeter-
sized proliferation of mild to moderately atypical pneumocytes,
which resembles but does not meet criteria for BAC.19,20
An indication that the updated definition of BAC is
beginning to have a clinical impact is in recent data from Zell
et al,22 who, based on data from the population-based cancer-
surveillance programs of three southern California counties
from 1995 to 2003, demonstrated that the median overall
survival for BAC patients diagnosed after May 1999 (53
months) was significantly improved compared with median
overall survival for BAC patients before May 1999 (32
months; p  0.012). This improved survival for BAC is best
explained by the change in diagnostic criteria in the 1999
WHO classification.
DISTRIBUTION OF BAC AND INVASIVE
ADENOCARCINOMA
There are several gross pathologic and radiologic ways
that BAC and mixed-subtype adenocarcinomas with a BAC
component can present in the lung, including a solitary
peripheral nodule (Figs. 4–6), multiple nodules (Figure 7),
and lobar consolidation (Figure 8).20,23–29 Adenocarcinomas
that consist mostly of a BAC component typically show a
ground-glass pattern by CT and an ill-defined gross appear-
ance (Figure 4). A grossly circumscribed nodule by patho-
logic exam and a solid appearance by CT (Figure 6) is the
typical appearance of purely invasive adenocarcinomas. A
mixture of these CT and gross pathologic characteristics may
be seen in mixed-subtype adenocarcinomas with both BAC
and invasive components (Figure 5). When BAC or adeno-
carcinoma presents with multiple nodules, they can be uni-
lateral (Figure 6) or bilateral. Unilateral nodules can present
as a large dominant mass with satellite nodules within the
same lobe or with multiple nodules in more than one lobe.20,27,28
When BAC or adenocarcinoma presents with a pattern of lobar
consolidation, the tumor grows in a diffuse parenchymal infil-
tration pattern that is grossly and radiologically difficult to
distinguish from lobar pneumonia (Figure 8).20,28–30
Because of significant differences in pathologic, radio-
logic, and clinical implications among these patterns of pre-
sentation by lung adenocarcinoma, the following discussion
will be divided into two major categories: 1) solitary, small,
FIGURE 1. Adenocarcinoma, mixed
subtype. (A) A bronchioloalveolar
pattern is seen to the left, and an
invasive component is seen on the
right (hematoxylin and eosin 4).
(B) The invasive component consists
of solid nests and acinar glands infil-
trating a fibrous stroma (hematoxylin
and eosin 20).
FIGURE 2. Bronchioloalveolar carcinoma, nonmucinous
type. The alveolar walls are lined by a cellular proliferation of
atypical pneumocytes that have a hobnail morphology. No
invasion is seen.
FIGURE 3. Bronchioloalveolar carcinoma, mucinous type.
The alveolar walls are lined by a cellular proliferation of co-
lumnar cells with abundant apical mucin and small basally
oriented nuclei. No invasion is seen.
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peripheral lung nodules and 2) multicentric or diffuse con-
solidation patterns.
SOLITARY, SMALL, PERIPHERAL LUNG
NODULE
The basis for the 1999 WHO classification proposal for
the narrow definition of BAC19 was the 1995 publication by
Noguchi et al,14 who demonstrated that small peripheral lung
adenocarcinomas with a pure BAC pattern lacking invasion
had a 100% 5-year survival rate. They also showed that
patients with mixed BAC and invasive components had a
survival rate of 75% in contrast to those with purely invasive
growth patterns, who had a survival rate of 52%.14
This definition of BAC has several practical conse-
quences. First, small tumors 3 cm or less in diameter with a
predominant BAC component need to be entirely sampled for
potential foci of invasion to be detected. Also, because BAC
should show a pure lepidic growth without invasion, the
unequivocal diagnosis of BAC cannot be established based
on small biopsy specimens (needle or bronchoscopic speci-
mens). In addition, the diagnosis of BAC cannot be made
with certainty based on cytology specimens because an in-
vasive component cannot be definitely excluded by these
preparations, although there are certain cytologic features
that might suggest the presence of a BAC component within
the tumor.31
FIGURE 4. Nonsolid or ground-glass nodule. Chest CT im-
age shows a dominant nonsolid nodule (white arrow) in the
right lower lobe. An adjacent smaller nonsolid nodule is also
noted.
FIGURE 5. Part-solid nodule. Chest CT image shows a
2-cm nodule with central denser part surrounded by
ground-glass attenuation in the right lower lobe.
FIGURE 6. Solid nodule. Chest CT image focused on the
right upper lobe shows a 2-cm nearly homogeneously dense
nodule.
FIGURE 7. Multicentric adenocarcinoma. Chest CT image
shows multiple part-solid nodules in the right lower lobe.
Radiation fibrosis is noted in the left lower lobe posteriorly.
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Subsequently, other reports have examined solitary,
small, peripheral lung adenocarcinomas using different ap-
proaches to identify histologic prognostic factors.7,9,16,32 Each
study identified different histologic features to define a sub-
group of mixed-subtype adenocarcinomas that have a pre-
dominant BAC component and a favorable prognosis. These
prognostically important histologic features included size of
scar (5 mm or less, 5–15 mm, and greater than 15 mm),7,9
percentage of lepidic growth,9 percentage of papillary
growth,9 vascular invasion,9 size of invasive area (5 mm or
less versus greater than 5 mm),16 and pattern of stromal
invasion (within area of BAC growth, localized in the pe-
riphery of the scar, or in the center of the scar).32
The pathology panel at the November 2004 BAC meet-
ing in New York felt that the existing data were insufficient
to develop a definition of “minimally invasive” adenocarci-
noma with a predominant BAC component. The CT review
panel recognized three patterns of lung involvement in BAC
and adenocarcinoma: 1) ground-glass opacity or nonsolid; 2)
mixed-density or mixed-ground-glass opacity; and 3) solid
(Figs. 4–8).
The following prognostic factors have been shown by
CT based on the extent of ground-glass opacity,33–36 presence
of air bronchograms,23 lack of coarse spiculation, and thick-
ening of bronchovascular bundles around the tumors.34
MULTICENTRIC NODULES AND LOBAR
CONSOLIDATION
Although lung adenocarcinomas with multicentric nod-
ules and lobar consolidation may present a different clinical
problem than the solitary nodule cases because they have a
more advanced stage, the histologic patterns are the same.
Both mucinous and nonmucinous BAC can present with
diffuse or multicentric growth patterns; however, mucinous
tumors are more likely to have a multicentric or lobar con-
solidation presentation.
Pathologic Aspects
Most of the recent literature on the topic of adenocar-
cinomas with a BAC component that present as multicentric
nodules or lobar consolidation have been clinical studies
without incorporation of recent pathologic concepts.37–40
There are few detailed pathologic data according to current
concepts regarding multicentric/diffuse adenocarcinoma and
BAC. Study of these tumors is more problematic because
they are often unresectable, and the diagnosis is established
only by small biopsy or cytology specimens, with the atten-
dant issue of incomplete sampling of the tumor as mentioned
above. Review of biopsy material from multicentric lung
adenocarcinomas at the 2004 New York BAC meeting sug-
gested that the spectrum of histologic findings in multicentric
lung adenocarcinomas is similar to that in the solitary periph-
eral tumors; most of these tumors are adenocarcinoma, mixed
subtype with a varying spectrum of BAC, acinar, papillary,
and solid patterns.
According to the current American Joint Committee on
Cancer staging system, patients with a second tumor showing
the same histology in the same lobe are classified as having
a T4 lesion, thus representing stage 3B.41 In addition, patients
with a tumor with the same histology in a separate lobe are
classified as M1, and the patient is considered to have stage
4 disease.41 Recent studies by Battafarano et al37 and Roberts
et al42 indicate that tumors presenting as multiple small
peripheral adenocarcinomas or BAC presenting as multifocal
disease may be amenable to surgical resection with prolonged
survival. These data suggest that a revision of the staging of
BAC and adenocarcinomas with multiple nodules may be
necessary.
Radiologic Aspects
When lung adenocarcinomas with or without BAC
present with multiple nodules, the CT features of each of the
nodules may have the same spectrum of findings described
above in the solitary nodules. Diffuse BAC or adenocarci-
noma shows a combination of consolidation and nodules and
the coexistence of centrilobular nodules and remote areas of
ground-glass attenuation.30 The differential diagnosis in-
cludes pneumonia and lymphoma (Figure 8).30
CONCLUSIONS
Advances in the understanding of the pathology and CT
features of BAC and adenocarcinoma, which have led to
changes in diagnostic criteria and classification, need to be
uniformly applied by pathologists, radiologists, clinicians,
and researchers. The 2004 WHO classification of adenocar-
cinoma is readily applicable to research studies, but attention
needs to be placed on the relative proportion of the adeno-
carcinoma subtypes because there seems to be a prognostic
importance to the amount of BAC versus invasive subtype
(acinar, papillary, and solid) components of lung adenocar-
cinomas.7,9,16,32 Other recently recognized prognostic features
such as size of scar, size of invasive component, or pattern of
invasion also seem to be important. Emerging data also
suggest molecular differences according to histologic subtype
of lung adenocarcinoma. Given the many sophisticated mo-
FIGURE 8. Bilateral multifocal adenocarcinoma. Chest CT
image shows nodular and patchy areas of consolidation in
lower lobes, right middle lobe. and lingula.
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lecular and clinical studies being undertaken, including those
focused on molecular changes and chemotherapeutic agents
targeting the human epidermal growth factor receptor, such
as gefitinib, cetuximab, and erlotinib,10 it is important to
carefully define the pathology of the adenocarcinomas from
the patients involved in these studies so that it will be clear
what types of patients are being evaluated.
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